Drug Shortage Threat From Second COVID-19 Wave
Problems Are Expected But API Supplies May Not Be At Great Risk
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
You may also be interested in...
A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.
Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.